Re:Search Institution Members

149 Results for Members


Operation ASHA is dedicated to bringing tuberculosis treatment and health services to the poorest of the poor...

Public Interest Intellectual Property Advisors, Inc. (PIIPA) is an international non-profit organization that...

The Icahn School of Medicine at Mount Sinai (ISMMS), formerly Mount Sinai School of Medicine, is an American...

International Centre for Genetic Engineering and Biotechnology is a center of excellence for research,...

The University of Campinas (Unicamp), is a public research university in the state of São Paulo, Brazil. It...

The Indian Council of Medical Research (ICMR) is one of the oldest medical research bodies in the world. The...

162 Results for Collaborations


The NIH will provide IDRI researchers with natural product extracts to screen against M. tuberculosis.

The NCI/NIH provided IDRI researchers with natural products to test against kinetoplastids.

Researchers from IP Tunis will be utilizing the NIAID/NIH pre-clinical services program to increase thermostability of IP Tunis’ investigational rabies vaccine.

A National Institute of Parasitic Diseases, China CDC (NIPD) researcher will sequence the K13 gene of Plasmodium falciparum parasites found within malaria patient blood samples obtained by researchers at the Centre Pasteur du Cameroun (CPC). The researchers seek to assess the development of artemisinin resistance in Plasmodium parasites circulating in Cameroon, and to compare parasite genotypes with the patients’ responses to treatment – specifically parasite clearance.

A NIPD researcher sequenced the K13 gene of a set of malaria parasites obtained from Senegalese malaria patients by a University Cheikh Anta Diop of Dakar researcher. The sequences obtained informed the researchers of the mutations occurring in that gene and the likelihood of the development of artemisinin resistance.

A University of Ibadan researcher collaborated with an NIPD researcher to work on serum samples from Nigerian schistosomiasis patients. The NIPD researcher hosted a post-doctoral scientist from Nigeria to identify potential Schistosoma mansoni and S. haematobium antigens to incorporate into a schistosomiasis rapid diagnostic.

170 Results for Assets


Growing evidence suggests that the presence of a subpopulation of hypoxic non-replicating phenotypically drug resistant mycobacteria is responsible for lengthy tuberculosis treatment. The respiratory functions were demonstrated to represent the Achille's heel of hypoxic non-replicating Mycobacterium tuberculosis. Here, we describe the development of a hypoxic model optimized to identify compounds targeting the mycobacterial respiratory functions and ATP homeostasis in a whole-cell screen. The model was adapted to the 1536-well plate format and successfully used to screen over 600,000 compounds. 900 compounds were confirmed to reduce intracellular ATP levels in a dose-dependant manner. 155 non-cytotoxic scaffolds with anaerobic activity against hypoxic non-replicating M. tuberculosis were identified. This collection of disruptors of ATP homeostasis represents a valuable tool to decipher the biology of persistent mycobacteria.
5 series, Total of 371 exemplified compounds, Pending patent applications
Nucleic acid, recombinant vector, host cells, expression systems, 289 compounds, exemplified in 1 series, 2 granted patents and pending patent applications.
TRC is looking to develop partnerships with interested parties wishing to gain access to its comprehensive parasite bank, for the purposes of genetic sequencing and / or the development of new diagnostic tools and vaccines. The bank contains all human trypanosomes, all animal infective parasites, DNA from vectors of Trypanosomiasis.
TRC is looking for partners interested in working towards the commercialization of its Infectra-kit, an acrylic mouse restraint device for vector infection studies. The device allows essential transmission studies to be carried out with minimal human manipulation and without the need for anaesthesia. Infectra®-kit can be used as a single unit for restraining one mouse or as eight-assembled units, thus significantly improving efficiency of a single operator in comparison to manual restraint. The device has been validated for use in Trypanosomiasis research, and is undergoing validation for use in malaria research. • Has a single-fly holding cage and en mass fly holding cage. • Interaction of mouse with vector is facilitated through wire mesh fitted on the restrainer. • Allows for ventral or dorsal inoculation of the mouse. • Authors verified its use by comparing tsetse fly feeding rates on mice in the Infectra®-Kit vs. manual hand-holding.
TRC maintains significant animal testing facilities, including the capacity to hold up to 150 primates. TRC is looking to enter into collaborative partnerships, including contract research, for organizations wishing to undertake in vivo pre-clinical studies into the safety and toxicity of drug candidates and diagnostic tools, using its primate model.